Advancing the Development of Imsidolimab with AnaptysBio
We are excited to share some good news! Congratulations AnaptysBio on the orphan drug designation of imsidolimab for the treatment of GPP! We are thrilled to manage this clinical trial and help advance the development of imsidolimab.
For more information on our services, visit https://innovaderm.com/full-service-dermatology-cro/
AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation.